Hasil Pencarian - Yasushi Goto, MD, PhD

  • Menampilkan 1 - 14 hasil dari 14
Perbaiki Hasil
  1. 1
    The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy

    The Long Half-Life of Programmed Cell Death Protein 1 Inhibitors May Increase the Frequency of Immune-Related Adverse Events After Subsequent EGFR Tyrosine Kinase Inhibitor Therapy oleh Yuki Shinno, MD, Yasushi Goto, MD, PhD, Mayu Ohuchi, Akinobu Hamada, Hiroshi Nokihara, Yasuhiro Fujiwara, Yuichiro Ohe

    Diterbitkan 2020-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study

    Long-Term Efficacy and Safety of Lorlatinib in Japanese Patients With ALK-Positive Advanced NSCLC—A Brief Report From the CROWN Study oleh Shunsuke Teraoka, MD, Hidetoshi Hayashi, MD, PhD, Yasushi Goto, MD, PhD, Makoto Nishio, MD, PhD, Shunichi Sugawara, MD, PhD, Takao Inoue, MD, Satoshi Oizumi, MD, PhD, Shigeyuki Toyoizumi, MS, Masakazu Matsumura, MS, Rossella Messina, PharmD, PhD, Terufumi Kato, MD

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN

    First-Line Lorlatinib Versus Crizotinib in ALK-Positive NSCLC: Japanese Subgroup Analysis of CROWN oleh Hidetoshi Hayashi, MD, PhD, Shunsuke Teraoka, MD, Yasushi Goto, MD, PhD, Toru Kumagai, MD, PhD, Makoto Nishio, MD, PhD, Shunichi Sugawara, MD, PhD, Satoshi Oizumi, MD, PhD, Masakazu Matsumura, MS, Masayuki Okura, PhD, Gerson Peltz, MD, MPH, Terufumi Kato, MD

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC—Real-World Data in the Era of Molecularly Targeted Agents and Immunotherapy

    Efficacy of Adjuvant Chemotherapy With Tegafur-Uracil in Patients With Completely Resected, Node-Negative NSCLC—Real-World Data in the Era of Molecularly Targeted Agents and Immuno... oleh Takehito Shukuya, MD, PhD, Kazuya Takamochi, MD, PhD, Hiroyuki Sakurai, MD, PhD, Kiyotaka Yoh, MD, Tomoyuki Hishida, MD, PhD, Masahiro Tsuboi, MD, PhD, Yasushi Goto, MD, PhD, Yujin Kudo, MD, PhD, Yasuhisa Ohde, MD, PhD, Sakae Okumura, MD, Masataka Taguri, PhD, Hideo Kunitoh, MD

    Diterbitkan 2022-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report

    Rapid Response to Lenvatinib and Disease Flare After Discontinuation in a Patient With Thymic Carcinoma Harboring KIT Exon 11 Mutation: A Case Report oleh Masahiro Torasawa, MD, Tatsuya Yoshida, MD, PhD, Kouya Shiraishi, PhD, Naoko Goto, BS, Toshihide Ueno, PhD, Hitoshi Ichikawa, MD, PhD, Shigehiro Yagishita, MD, PhD, Shinji Kohsaka, MD, PhD, Yasushi Goto, MD, PhD, Yasushi Yatabe, MD, PhD, Akinobu Hamada, PhD, Hiroyuki Mano, MD, PhD, Yuichiro Ohe, MD, PhD

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan

    First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan oleh Yasushi Goto, MD, PhD, Atsuhisa Tamura, MD, PhD, Hirotaka Matsumoto, MD, Kazutoshi Isobe, MD, PhD, Tomohiro Ozaki, MD, Melissa L. Santorelli, PhD, MPH, Kazuko Taniguchi, MS, Tetsu Kamitani, MD, PhD, Masato Irisawa, PhD, Kingo Kanda, MPharm, Machiko Abe, MS, Thomas Burke, PharmD, PhD, Hiroshi Nokihara, MD, PhD

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Health Care Resource Use Among Patients with Advanced Non–Small Cell Lung Cancer in Japan, 2017–2019

    Health Care Resource Use Among Patients with Advanced Non–Small Cell Lung Cancer in Japan, 2017–2019 oleh Yasushi Goto, MD, PhD, Kodai Kawamura, MD, PhD, Tatsuro Fukuhara, MD, PhD, Yukiko Namba, MD, PhD, Keisuke Aoe, MD, PhD, Takehito Shukuya, MD, PhD, Takeshi Tsuda, MD, Melissa L. Santorelli, PhD, MPH, Kazuko Taniguchi, MS, Tetsu Kamitani, MD, PhD, Masato Irisawa, PhD, Kingo Kanda, MPharm, Machiko Abe, MS, Thomas Burke, PharmD, PhD, Hiroshi Nokihara, MD, PhD

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC

    Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC oleh Hitomi Jo, MD, PhD, Tatsuya Yoshida, MD, PhD, Shigehiro Yagishita, MD, PhD, Mayu Ohuchi, PhD, Yuji Matsumoto, MD, PhD, Yuki Shinno, MD, PhD, Yusuke Okuma, MD, PhD, Yasushi Goto, MD, PhD, Hidehito Horinouchi, MD, PhD, Noboru Yamamoto, MD, PhD, Kazuhisa Takahashi, MD, PhD, Noriko Motoi, MD, PhD, Akinobu Hamada, PhD, Yuichiro Ohe, MD, PhD

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005)

    Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005) oleh Jiyun Lee, MD, Aaron C. Tan, BSc, M.B.B.S., PhD, FRACP, Siqin Zhou, MSc Statistics, Shinkyo Yoon, MD, PhD, Siyang Liu, MD, PhD, Ken Masuda, MD, Hidetoshi Hayashi, MD, PhD, Ullas Batra, MD, DM, Dong-Wan Kim, MD, PhD, Yasushi Goto, MD, PhD, Sze Huey Tan, PhD, Yi-Long Wu, MD, Dae Ho Lee, MD, PhD, Daniel S.W. Tan, BSc, M.B.B.S., MRCP, PhD, Myung-Ju Ahn, MD, PhD

    Diterbitkan 2022-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL

    Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAIL oleh Shigehiro Yagishita, MD, PhD, Yasushi Goto, MD, PhD, Makoto Nishio, MD, PhD, Hiroaki Akamatsu, MD, PhD, Hidetoshi Hayashi, MD, PhD, Satoru Miura, MD, PhD, Koji Tamada, MD, PhD, Hiroshi Kagamu, MD, PhD, Akinobu Hamada, PhD, Mayu Ohuchi, PhD, Akihiko Gemma, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Akito Hata, MD, Satoshi Hara, MD, Takashi Kijima, MD, PhD, Fujita Masaki, MD, PhD, Shunichiro Iwasawa, MD, PhD, Shintaro Nakagawa, MSc, Masahiro Tatsuno, MSc, Tetsuya Mitsudomi, MD, PhD

    Diterbitkan 2024-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan

    A Retrospective, Multicenter, Observational Study to Evaluate Clinical Outcomes of Lorlatinib After Alectinib in Patients With ALK-Positive NSCLC in Japan oleh Yasushi Goto, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Motohiro Tamiya, MD, Shuji Murakami, MD, Takayasu Kurata, MD, Noriko Yanagitani, MD, Hirokazu Taniguchi, MD, PhD, Shoichi Kuyama, MD, PhD, Junichi Shimizu, MD, PhD, Toshihide Yokoyama, MD, Naoko Shimada, MD, PhD, Tadashi Maeda, MD, Akihiro Tamiya, MD, Ayumi Uchiyama, MD, Kazuyoshi Imaizumi, MD, Takayuki Takahama, MD, PhD, Terufumi Kato, MD, Hidetoshi Hayashi, MD, PhD, Naoko Shiraiwa, MSc, Shigeyuki Toyoizumi, MSc, Hironori Kikkawa, PhD, Despina Thomaidou, MSc, Makoto Nishio, MD, PhD

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observational Study (J-TAIL)

    Effectiveness and Safety of Atezolizumab Monotherapy in Previously Treated Japanese Patients With Unresectable Advanced or Recurrent NSCLC: A Multicenter, Prospective, Observationa... oleh Satoru Miura, MD, PhD, Makoto Nishio, MD, PhD, Hiroaki Akamatsu, MD, PhD, Yasushi Goto, MD, PhD, Hidetoshi Hayashi, MD, PhD, Akihiko Gemma, MD, PhD, Ichiro Yoshino, MD, PhD, Toshihiro Misumi, PhD, Akito Hata, MD, Osamu Hataji, MD, PhD, Kohei Fujita, MD, PhD, Masahiro Seike, MD, PhD, Noriko Yanagitani, MD, PhD, Kazumi Nishino, MD, PhD, Satoshi Hara, MD, Ryota Saito, MD, PhD, Masahide Mori, MD, PhD, Takeshi Tsuda, MD, Shunichiro Iwasawa, MD, PhD, Shintaro Nakagawa, MSc, Tetsuya Mitsudomi, MD, PhD

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC

    Asian Subgroup Analysis of the Randomized Phase 3 CROWN Study of First-Line Lorlatinib Versus Crizotinib in Advanced ALK-Positive NSCLC oleh Qing Zhou, MD, PhD, Ross A. Soo, MBBS, PhD, Gee-Chen Chang, MD, PhD, Chao-Hua Chiu, MD, Hidetoshi Hayashi, MD, PhD, Sang-We Kim, MD, PhD, Shunsuke Teraoka, MD, Yasushi Goto, MD, PhD, Jianying Zhou, MD, Victor Ho-Fun Lee, MD, Dong-Wan Kim, MD, PhD, Baohui Han, MD, PhD, James Chung Man Ho, MD, FRCP, Chia-Chi Lin, MD, PhD, Shun Lu, MD, Anna Polli, BS, Anna Maria Calella, PhD, Jean-François Martini, PhD, Chew Hooi Wong, PhD, Tony Mok, MD, Hye Ryun Kim, MD, PhD, Yi-Long Wu, MD

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations

    Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations oleh Kiichiro Ninomiya, MD, PhD, Shunsuke Teraoka, MD, Yoshitaka Zenke, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Yukiko Nakamura, MD, Yusuke Okuma, MD, PhD, Akihiro Tamiya, MD, Kaname Nosaki, MD, Masahiro Morise, MD, PhD, Keiju Aokage, MD, Yuko Oya, MD, Toshiyuki Kozuki, MD, PhD, Tomohiro Sakamoto, MD, PhD, Kentaro Tanaka, MD, PhD, Hisashi Tanaka, MD, PhD, Junko Tanizaki, MD, PhD, Satoru Miura, MD, PhD, Hideaki Mizutani, MD, Eisaku Miyauchi, MD, PhD, Ou Yamaguchi, MD, PhD, Noriyuki Ebi, MD, Yasushi Goto, MD, PhD, Takaaki Sasaki, MD, PhD, Haruko Daga, MD, PhD, Satoshi Morita, PhD, Takeharu Yamanaka, PhD, Shinsuke Amano, BCom, Kazuo Hasegawa, BFA, Chiyo K. Imamura, PhD, Kenichi Suzuki, PhD, Kazuko Nakajima, PhD, Hitomi Nishimoto, MN, Satoshi Oizumi, MD, PhD, Toyoaki Hida, MD, PhD, Katsuyuki Hotta, MD, PHD, MPH, Yuichi Takiguchi, MD, PhD

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: